Ichnos Glenmark Innovation (IGI) has submitted an Investigational New Drug (IND) application to the U.S. FDA for ISB 2301. This first-in-class pentaspecific immunocell activator is designed to target three tumor-associated antigens while activating both T-cells and NK-cells to combat solid tumors. The company plans to initiate a Phase-1 clinical trial for the candidate in 2027.
Ichnos Glenmark Innovation filed an IND application with the FDA for ISB 2301, a first-in-class pentaspecific immunocell activator, and plans a Phase-1 study in solid tumours in 2027. This is an early, routine regulatory step, not an approval or clinical result, so it does not materially change the outlook for the listed parent in the coming days to weeks.